TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06404112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melantonin Placebo
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melantonin Placebo
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored lighting (TL) Active
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored lighting (TL) Active
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored lighting (TL) Placebo
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tailored lighting (TL) Placebo
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study: NCT04978896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-guided program on stress coping
Description: This is an 8-day program that provides psychoeducation on the negative effects of stress and effective stress-management skills to combat stress. Guided by principles of CBT, the program targets the thoughts and behaviours of participants and equips them with skills to alter negative cognitions pertaining to stress. Participants are engaging with a series of exercises involving reflection and mindfulness where they are required to spot and write down their stressors, the negative thoughts associated with the stressors, as well as positive affirmations. Participants will also be taught breathing exercises and are encouraged to practice them during 2 check-ins.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided program on cooperation
Description: The 8-day program on cooperation aims to provide psychoeducation for participants to understand and improve collaboration and interpersonal relationships. Short quizzes and practice exercises on feedback-giving will be included. The time and duration of the cooperation SGA is matched to the stress-coping SGA to ensure that participants spend a similar amount of time and effort across both the intervention and active-control conditions.
Study: NCT05263739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion
Study: NCT05440877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR materials
Description: In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutorial guide
Description: A tutorial guide including description of the smokers' cases

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutorial guide
Description: A tutorial guide including description of the smokers' cases
Study: NCT04213300

Intervention type: OTHER
Intervention: Low carbohydrate diet
Description: Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) .
Study: NCT06438822

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil
Description: cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2 for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m2 for 30 min on day 1 and fluorouracil at a dosage of 400 mg/m2 for 46 h every 2 weeks.
Study: NCT05533346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: with WISE (Walking Instruction based on Self-Efficacy)
Description: Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: without WISE (Walking Instruction based on Self-Efficacy)
Description: The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
Study: NCT06345248

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-TAP
Description: regional block team under ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPTAP
Description: performed TAP block under direct visualization with the laparoscope
Study: NCT04697966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness (Headspace) App
Description: The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Condition (Recharge condition delivered in Headspace app)
Description: The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises.
Study: NCT05442996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX35
Description: The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
Study: NCT05467423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: 4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: 4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
Study: NCT05681650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HypoSti.CAR-HER2 T cells
Description: Dose escalation: dose -1 (1×10\^6 cells/kg) ,dose 1 (3×10\^6 cells/kg) , dose 2 (6×10\^6 cells/kg), dose 3 (1×10\^7 cells/kg), dose 4 (1.5×10\^7 cells/kg). Dose expansion: RP2D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered intravenously at dose of 100-200mg/m2 on day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
Study: NCT05821985

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The study group
Description: The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The Control group
Description: The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution.
Study: NCT05250505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eShunt Implant
Description: The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
Study: NCT03909893

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiation Therapy
Description: Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
Study: NCT05401162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with haematopoietic stem cells
Description: Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Study: NCT06523335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular coordination-guided rehabilitative training
Description: During training exercise, post-stroke participants will be asked to match the targets on the screen. The experimental group will match them by activating a specific set of muscle. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Force strengthening-guided rehabilitative training
Description: During training exercise, post-stroke participants will be asked to match the targets on the screen. The active comparator group will match them by generating isometric force in a desired target direction. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
Study: NCT05730725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04756765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
Study: NCT05454774

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single dose intravenous injection of BBM 002
Description: Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg
Study: NCT05866770

Intervention type: DEVICE
Group type: OTHER
Intervention: U8
Description: The U8 Research System

Intervention type: DEVICE
Group type: OTHER
Intervention: U8
Description: The U8 Research System

Intervention type: DEVICE
Group type: OTHER
Intervention: N8 sound processor
Description: Nucleus 8 sound processor

Intervention type: DEVICE
Group type: OTHER
Intervention: N8 sound processor
Description: Nucleus 8 sound processor
Study: NCT05412147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RECO-18
Description: 4 pills daily, oral

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-vitamins
Description: one tablet daily, oral
Study: NCT05427981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca Buccal Product
Description: Buprenorphine Buccal Films

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Buccal Films
Study: NCT06005415

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wire-cut cookie
Description: Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wire-cut cookie
Description: Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
Study: NCT04761601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-01-097
Description: Orally available kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-01-097
Description: Orally available kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-01-097
Description: Orally available kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine injection for intravenous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
Study: NCT04975698

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HST-NEETs
Description: HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10\^7/m\^2 cells between 3 Days and 7 Days post-ASCT.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bone Marrow Transplant
Description: Day 0 is the day of bone marrow transplantation.
Study: NCT06466577

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT 5400 RT System
Description: Computed Tomography X-RAY System is intended to produce images of the head and body by computer reconstruction of x-ray transmission data taken at different angles and planes.
Study: NCT05767008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen -R43
Description: Long wear metal oxide particles
Study: NCT05241262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
Study: NCT06432634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The pre-operative educational session has a duration of 40 minutes and covers pre-operative education, breathing exercises (diaphragmatic breathing, deep breathing techniques and sustained maximal inflation), and airway clearance techniques (directed cough, huffing, and chest physiotherapy). Patients are instructed to perform these techniques ten times per waking hour, every day. The in-patient peri-operative session incorporates intermittent positive pressure breathing inhalation (IPPB) administered for 15 minutes twice daily. Inhalation therapy involving mucolytics and bronchodilators is administered three times per day, and early mobilization is encouraged until discharge. Upon discharge, participants are encouraged to continue practicing breathing exercises, deep breathing techniques, and maintaining an active level of activity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: The pre-operative educational session has a duration of 40 minutes and covers pre-operative education, breathing exercises (diaphragmatic breathing, deep breathing techniques and sustained maximal inflation), and airway clearance techniques (directed cough, huffing, and chest physiotherapy). Patients are instructed to perform these techniques ten times per waking hour, every day. The in-patient peri-operative session incorporates intermittent positive pressure breathing inhalation (IPPB) administered for 15 minutes twice daily. Inhalation therapy involving mucolytics and bronchodilators is administered three times per day, and early mobilization is encouraged until discharge. Upon discharge, participants are encouraged to continue practicing breathing exercises, deep breathing techniques, and maintaining an active level of activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive pulmonary rehabilitation programs
Description: 1. Warm-up and cool-down exercises: stretching various muscle groups for a duration of 15 to 20 minutes and a slow 3-minute walk~2. Aerobic training: using a lower-limb cycle ergometer for a duration of 30 to 40 minutes. Initiated warm-up at 0 wattages for 5 minutes. Incrementally increased wattages within 5-10 minutes until reaching the 40-80% heart rate reserve or 4 to 6 of modified Borg scale for at least 20 minutes. Concludes with a 5-minute cool-down period at 10 wattages.~3. The resistance training involves both upper and lower limbs:~（1） Upper Limb Resistance Training: Shoulder lift, abduction, and horizontal abduction exercises are performed. Each exercise is repeated for three sessions comprising 10 repetitions each. A 0.5-2 kg dumbbell is utilized for resistance.~（2） Lower Limb Resistance Training: Sit-to-stand exercises are performed. Each session consists of three sets of 10 repetitions.
Study: NCT04144153

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Opioid Free Total Intravenous Anesthesia
Description: Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Total Intravenous anesthesia with opioid
Description: Total Intravenous anesthesia with opioid
Study: NCT06304961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Tozorakimab will be administered as a single SC dose on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Tozorakimab will be administered as a single SC dose on Day 1.
Study: NCT05208476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative medicine
Description: A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
Study: NCT05251714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257
Description: Oral once daily in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257
Description: Oral once daily in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle